Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12685282 | 0.91 | KDM4E (0.42) | HRH3SLC6A4KDM4EUSP2ALDH1A1 | |
| SCHEMBL23291149 | 0.91 | HRH3 (0.35) | HRH3SLC6A4KDM4EUSP2ALDH1A1 | |
| SCHEMBL15884760 | 0.84 | KDM4E (0.48) | HRH3SLC6A4KDM4EUSP2ALDH1A1 | |
| SCHEMBL23291205 | 0.81 | KDM4E (0.36) | HRH3SLC6A4KDM4EUSP2ALDH1A1 | |
| SCHEMBL15885313 | 0.81 | MMP9 (0.45) | HRH3SLC6A4KDM4EUSP2ALDH1A1 | |
| SCHEMBL15884868 | 0.79 | ALDH1A1 (0.54) | HRH3KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL6186091 | 0.77 | KDM4E (0.52) | HRH3KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14131261 | 0.74 | S1PR1 (0.41) | HRH3SLC6A4OPRM1 | |
| SCHEMBL29023023 | 0.74 | OPRM1 (0.40) | HRH3SLC6A4OPRM1BDKRB1 | |
| SCHEMBL12409043 | 0.73 | HRH3 (0.38) | HRH3SLC6A4KDM4EOPRM1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663463-B2 | 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20160280645-A1 | NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSE | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| EP-3072884-A1 | NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280645-A1 | NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSE | OPRM1, OPRD1, OPRK1 | HRH3 67/4885SLC6A4 676/4885KDM4E 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.